EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.52) per share which met the analyst consensus estimate. This is a 23.81 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $11.56 million which beat the analyst consensus estimate of $10.87 million by 6.39 percent. This is a 28.31 percent increase over sales of $9.01 million the same period last year.
Meta Platforms Price Target Cut By This Analyst, Plus BMO Capital Predicts $223 For Salesforce
Morgan Stanley boosted the price target for Meta Platforms, Inc. (NASDAQ: META) from $280 to $225. Meta shares fell 2.1% to $171.01 in pre-market trading.
